CLXT News and Press, Calyxt Inc. From 03/03/22

Calyxt, Inc. (CLXT) Q4 2021 Earnings Conference Call March 3, 2022, 4:30 PM ET Company Participants Bill Koschak - Chief Financial Officer Michael Carr - President and CEO Conference Call Participants Laurence Alexander - Jefferies Bobby Burleson - Canaccord Brian Wright - ROTH Capital Partne...

Calyxt press release (NASDAQ:CLXT): Q4 GAAP EPS of -$0.55 misses by $0.26. Revenue of $12.20M (-12.4% Y/Y) beats by $9.56M. For further details see: Calyxt GAAP EPS of -$0.55 misses by $0.26, revenue of $12.20M beats by $9.56M

Calyxt Reports Fourth Quarter and Full Year 2021 Financial Results Reported achievement of milestones in the operationalization of its BioFactory™ production system, including the startup of its initial 200-liter pilot facility Continued to expand AIML capabilities ac...

Calyxt (NASDAQ:CLXT) is scheduled to announce Q4 earnings results on Thursday, March 3rd, after market close. The consensus EPS Estimate is -$0.23 (+30.3% Y/Y) and the consensus Revenue Estimate is $2.64M (-81.0% Y/Y). Over the last 1 year, CLXT has beaten EPS estimates 0% of the time and has...

ACR, AQN, AVAV, AVGO, BCEL, CEMI, CLLS, CLXT, COO, COST, OTCPK:CURLF, DBVT, DUOL, EGLE, ENVX, EOLS, ESTC, EVFM, FCRD, FDUS, FNKO, GPS, INMB, OTCPK:MEGEF, MRVL, NCMI, ONCY, PAYO, PBYI, SIGA, SWBI, VERI, VZIO For Seeking Alpha's full earnings season calendar, click here. For further details s...

Calyxt to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on Thursday, March 3, 2022, at 4:30 p.m. Eastern Time PR Newswire ROSEVILLE, Minn. , Feb. 24, 2022 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biol...

Calyxt Announces Closing of SEC-Registered Offering of Common Stock, Pre-Funded Warrants to Purchase Common Stock and Warrants to Purchase Common Stock PR Newswire ROSEVILLE, Minn. , Feb. 23, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ: CLXT) ("Calyxt" or the "Comp...

NEW YORK, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, and Calyxt, Inc. (“Calyxt”), a majority-owned (6...

Calyxt (NASDAQ:CLXT) announced the placement to an institutional investor in an underwritten offering of 3.88M shares of its common stock, pre-funded warrants to purchase up to 3.88M shares of its common stock, and warrants to purchase up to 7.76M shares. The gross proceeds are expected to be...

Calxyt, Inc. Announces Pricing of $10.9 Million SEC-Registered Offering of Common Stock and Warrants PR Newswire ROSEVILLE, Minn. , Feb. 17, 2022 /PRNewswire/ -- Calyxt, Inc. (NASDAQ: CLXT) ("Calyxt" or the "Company"), a plant-based synthetic biology company, tod...